🌐Machine-translated with AI — the facts come from the issuing authority’s own notice (linked on this page); this language version was translated automatically by an AI model and is not reviewed. The original-language notice is authoritative. How we use AI →
Reported risk: Výrobek obsahuje nadměrné množství kapaliny s nikotinem (naměřená hodnota: 18 ml). To může vést k náhodné konzumaci vysoké dávky nikotinu. Nikotin je akutně toxický a může ohrozit bezpečnost uživatele, zejména pokud přijde do kontaktu s kůží nebo je požit. Kromě toho je výrobek nedostatečně označen, protože jednotkové balení neobsahuje informace o množství nikotinu v dávce ani úplný seznam složek. Výrobek není v souladu s požadavky směrnice o tabákových výrobcích.
Action taken by the authority
Type of economic operator taking notified measure
Retailer
Category of measure
Recall of the product from end users
Date of entry into force
24/04/2024
Machine translation. This page was translated automatically from the English record we hold of the issuing authority’s notice. The English original is shown below and the authority’s own notice is linked above — both take precedence over this translation.
Product Name (original English): AROMA KING, BLUE RAZZ KUSH
Risk Description (original English): The product has an excessive amount of nicotine-containing liquid (measured value: 18ml). This can lead to the accidental consumption of a high dose of nicotine. Nicotine is acutely toxic and can endanger the user’s safety, notably if the product comes into contact with the skin or is ingested. Moreover, the product is insufficiently labelled, as the unit packaging does not include information on the amount of nicotine in the dose, or a complete list of ingredients.
Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.
ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.